Effect of montelukast on nuclear factor κB activation and proinflammatory molecules

Annals of Allergy, Asthma and Immunology

Volumn 94, Issue 6, 2005, Pages 670-674

  Maeba, Shinji ^a   Ichiyama, Takashi ^a   Ueno, Yoshiko ^a   Makata, Haruyuki ^a   Matsubara, Tomoyo ^a   Furukawa, Susumu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MONTELUKAST; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; LEUKEMIA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 20544433142     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61326-9     Document Type: Article

References (27)

1. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999; 399:789-793.
2. Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med. 2001; 163:226-233.
3. Wu AY, Chik SC, Chan AW, et al. Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy. 2003;33:359-366.
4. Frieri M, Therattil J, Wang SF, Huang CY, Wang YC. Montelukast inhibits interleukin-5 mRNA expression and cysteinyl leukotriene production in ragweed and mite-stimulated peripheral blood mononuclear cells from patients with asthma. Allergy Asthma Proc. 2003;24:359-366.
5. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol. 1990;10:1498-1506.
6. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-κ transcription factor. Mol Cell Biol. 1990;10:2327-2334.
7. Hiscott J, Marois J, Garoufalis J, et al. Characterization of a functional NF-κB site in the human interleukin 1β promoter: evidence for a positive autoregulatory loop. Mol Cell Biol. 1993;13:6231-6240.
8. Matsusaka T, Fujikawa K, Nishio Y, et al. Transcription factors NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A. 1993;90:10193-10197.
9. Kunsch C, Lang RK, Rosen CA, Shannon MF. Synergistic transcriptional activation of the IL-8 gene by NF-κB p65 (RelA) and NF-IL-6. J Immunol. 1994;153:153-164.
10. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol. 1994;12:141-179.
11. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
12. Brown K, Gerstberger S, Carlson L, et al. Control of NF-κB proteolysis by site-specific, signal-induced phosphorylation. Science. 1995;267:1485-1488.
13. Kumar A, Haque J, Lacoste J, et al. Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating IκB. Proc Natl Acad Sci U S A. 1994;91: 6288-6292.
14. Pyatt DW, Stillman WS, Yang Y, et al. An essential role for NF-κB in human CD34(+) bone marrow cell survival. Blood. 1999;93:3302-3308.
15. Ichiyama T, Nishikawa M, Yoshitomi T, et al. Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother. 2001;45:44-47.
16. Ichiyama T, Hasegawa S, Umeda M, et al. Pranlukast inhibits NF-κB activation in human monocytes/macrophages and T cells. Clin Exp Allergy. 2003;33:802-807.
17. Jones TR, Labelle M, Belley M, et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1995;73: 191-201.
18. Leyko BT, Perlman B, Huang Y, Frieri M. Assessment of RANTES mRNA production and expression in respiratory syncytial virus (RSV) antigen-stimulated and IL-1β-stimulated A549 cells: inhibition via montelukast and budesonide [abstract]. Ann Allergy Asthma Immunol. 2004;92:115.
19. Ng DK, Law AK, Chau KW, Chan HK. Use of montelukast in the treatment of early childhood wheezing from clinical experience with three cases. Respirology. 2000;5:389-392.
20. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol. 2003;111:S18-S34.
21. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6:315-325.
22. Chen R, Gao B, Huang C, et al. Transglutaminase-mediated fibronectin multimerization in lung endothelial matrix in response to TNF-α. Am J Physiol Lung Cell Mol Physiol. 2000; 279:161-171.
23. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor κB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24: 1131-1138.
24. -/- mice: the role of mast cells. J Immunol. 1999;163:2160-2167.
25. Dunzendorfer S, Kaneider NC, Kaser A, et al. Functional expression of chemokine receptor 2 by normal human eosinophils. J Allergy Clin Immunol. 2001;108:581-587.
26. Rose CE Jr, Sung SS, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation. 2003;10:273-288.
27. Balani SK, Xu X, Pratha V, et al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene 1 receptor antagonist, in human plasma and bile. Drug Metab Dispos. 1997;25:1282-1287.